We are live on ! Find out more
ASMB icon

Assembly Biosciences

100 hedge funds and large institutions have $576M invested in Assembly Biosciences in 2019 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 42 increasing their positions, 26 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

183% more capital invested

Capital invested by funds: $204M → $576M (+$372M)

62% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 26

11% more call options, than puts

Call options by funds: $5.19M | Put options by funds: $4.66M

10% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 20

2% more funds holding

Funds holding: 98100 (+2)

0.53% more ownership

Funds ownership: 6.72%7.25% (+0.53%)

Holders
100
Holders Change
+2
Holders Change %
+2.04%
% of All Funds
1.97%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
22
Increased
42
Reduced
26
Closed
20
Calls
$5.19M
Puts
$4.66M
Net Calls
+$534K
Net Calls Change
-$4.82M
Name Holding Trade Value Shares
Change
Change in
Stake
LGM
26
Logos Global Management
California
$3.85M +$2.89M +15,667 New
EMFAT
27
Emerald Mutual Fund Advisers Trust
Pennsylvania
$3.3M -$3.86M -20,950 -61%
BCPEMI
28
Bain Capital Public Equity Management II
Massachusetts
$3.27M +$2.46M +13,333 New
IC
29
Ikarian Capital
Texas
$3.22M +$2.42M +13,122 New
Charles Schwab
30
Charles Schwab
California
$3.15M +$448K +2,434 +23%
Barclays
31
Barclays
United Kingdom
$3M +$1.11M +6,007 +97%
D.E. Shaw & Co
32
D.E. Shaw & Co
New York
$2.93M -$1.5M -8,132 -41%
B
33
Bailard
California
$2.64M +$1.98M +10,750 New
BFM
34
Boothbay Fund Management
New York
$2.59M +$402K +2,185 +26%
Marshall Wace
35
Marshall Wace
United Kingdom
$2.54M +$1.16M +6,302 +156%
Prudential Financial
36
Prudential Financial
New Jersey
$2.47M -$1.67M -9,044 -47%
Bank of New York Mellon
37
Bank of New York Mellon
New York
$2.35M +$220K +1,193 +14%
Two Sigma Investments
38
Two Sigma Investments
New York
$2.17M +$407K +2,208 +33%
SG Americas Securities
39
SG Americas Securities
New York
$1.9M +$1.43M +7,742 New
SFM
40
Sphera Funds Management
Israel
$1.81M -$487K -2,646 -26%
MIM
41
Monashee Investment Management
Massachusetts
$1.74M +$1.3M +7,083 New
Adage Capital Partners
42
Adage Capital Partners
Massachusetts
$1.59M +$1.19M +6,458 New
Two Sigma Advisers
43
Two Sigma Advisers
New York
$1.43M -$134K -725 -11%
Deutsche Bank
44
Deutsche Bank
Germany
$1.39M -$1.17M -6,376 -53%
OAM
45
Oxford Asset Management
United Kingdom
$1.37M -$1.92M -10,417 -65%
Allianz Asset Management
46
Allianz Asset Management
Germany
$1.26M +$947K +5,140 New
PCM
47
Pinz Capital Management
New York
$1.25M +$936K +5,082 New
Morgan Stanley
48
Morgan Stanley
New York
$1.22M -$1.73M -9,392 -65%
Goldman Sachs
49
Goldman Sachs
New York
$1.1M -$221K -1,199 -21%
Swiss National Bank
50
Swiss National Bank
Switzerland
$1.1M +$167K +909 +26%

ASMB Hedge Fund Activity: Q4 2019 in Review

100 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Assembly Biosciences (ASMB) for Q4 2019, worth a combined $576M — up 183% from $204M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new ASMB positions and 20 closed out — a net gain of 2 holders — while 42 added to existing stakes and 26 trimmed.

The largest buyer was EcoR1 Capital, adding an estimated $35.2M. The largest seller was Armistice Capital, cutting an estimated $20.1M.

  • 100 institutional investors held Assembly Biosciences (ASMB) as of Q4 2019, up from 98 in Q3 2019.
  • Funds reported $576M of Assembly Biosciences stock for Q4 2019, up 183% quarter-over-quarter.
  • 22 funds opened new Assembly Biosciences positions in Q4 2019 and 20 closed out, a net change of +2 holders.
  • The largest Assembly Biosciences buyer in Q4 2019 was EcoR1 Capital, an estimated $35.2M added.
  • The largest Assembly Biosciences seller in Q4 2019 was Armistice Capital, an estimated $20.1M sold.

Based on aggregated 13F filings for Q4 2019.